Insight

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Photo taken from Jordi Remon/X

Aug 9, 2024, 14:55

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:

“In the current landscape treatments for early stage NSCLC several challenges with immunotherapy (ICB) and TKIs remain unresolved.We describe current data and challenges in this setting: role ICB in stage II or PDL1<1%,adjuvant TKI for all?.

Thanks to all authors!”

unresolved

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Autors: Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, David O’Reilly, Jarushka Naidoo, Giannis Mountzios, Olaf Mercier, Lizza E. L. Hendriks, Jordi Remon

unresolved

Source: Jordi Remon/X

cancer David O’Reilly Giannis Mountzios Jarushka Naidoo Jordi Remon Lizza E. L. Hendriks Lodovica Zullo Martina Bortolot Olaf Mercier OncoDaily Oncology Pernelle Lavaud

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer